Core Viewpoint - Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. and its subsidiary Yihui Biotechnology (Shanghai) Co., Ltd. have successfully initiated Phase I clinical trials for their adjuvanted influenza virus subunit vaccines in Hubei province [1][4]. Group 1: Vaccine Development - The adjuvanted influenza virus subunit vaccine is designed to meet the vaccination needs of different populations, particularly targeting individuals aged 65 and above [4]. - The vaccine is administered via intramuscular injection in the deltoid muscle, with low-dose and high-dose groups receiving 0.25ml and 0.5ml per dose, respectively, for a total of one dose on day 0 [4]. - Preclinical studies indicate that the adjuvanted vaccine significantly enhances antibody levels and neutralizing antibody titers, providing a superior immune response for the elderly [4]. Group 2: Public Health Context - Influenza poses a significant public health burden, with the WHO estimating 3 to 5 million severe cases globally each year [3]. - In China, the average annual excess mortality due to respiratory diseases caused by influenza was approximately 88,000 from 2010 to 2015, highlighting the need for effective vaccination strategies [3]. - The overall vaccination rate for influenza in China remains low, with only 3.84% during the 2022-2023 flu season, indicating a critical gap in immunity [3]. Group 3: Company Overview - Zhonghui Biotechnology focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [5]. - The company has made significant investments in R&D, with approved clinical products including recombinant zoster vaccine and adjuvanted influenza virus subunit vaccine [6]. - The company has established large-scale production capabilities, with a first-phase facility covering approximately 68 acres and equipped with international-level GMP production lines for influenza vaccines [6].